AHAhmad Haidar

Ahmad Haidar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmad Haidar has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Author Correction: A Bayesian decision support system for automated insulin doses in adults with type 1 diabetes on multiple daily injections: a randomized controlled trial

    by Alessandra Kobayati, Anas El Fathi, Natasha Garfield, Laurent Legault, Adnan Jafar, Jean-François Yale, Michael A. Tsoukas, Ahmad Haidar

  • Open Access

    Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

    by Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua

  • Inter- and intra-physician variability in insulin injection adjustments compared with Bayesian algorithm recommendations in type 1 diabetes

    by Alessandra Kobayati, Michael A. Tsoukas, Natasha Garfield, Laurent Legault, Melissa-Rosina Pasqua, Jean-François Yale, Sara J. Meltzer, Simon S. Wing, Stéphanie Michaud, Vanessa Tardio, et al.

    Aims/hypothesis There is an unmet need for automated insulin adjustments for multiple daily injections in type 1 diabetes under unsupervised use. We aimed to assess the McGill decision support system (DSS), which comprises a Bayesian algorithm, by comparing its automated insulin adjustments with those made by endocrinologists. Methods We surveyed 13 Canadian endocrinologists who made mock insulin adjustments in three separate parts on retrospective participants’ data. Part A (weekly data) and part C (biweekly data) compared the recommendations from physicians with those of the algorithm. Part B evaluated intra-physician variability by comparing the recommendations made by the same physician over time based on an identical dataset to part A. Results In part A, the agreement rate (mean [SD]) on the direction of weekly adjustments between the algorithm and physicians was non-inferior to the agreement rate between physicians for prandial bolus (55% [5] vs 56% [7], respectively; p=0.006) and basal insulin (48% [6] vs 51% [11], respectively; p=0.037). Low full disagreement rates on weekly adjustments were also comparable between the pairs for prandial bolus (3.9% [2.3] vs 4.1% [2.3], respectively; p=0.006) and basal insulin (10.6% [4.6] vs 9.2% [7.1], respectively; p=0.23). Similar rates were observed for biweekly insulin adjustments in part C. When comparing intra-physician decisions in part A with those in part B, on average, physicians fully agreed with themselves 66% (SD 7) and 67% (SD 7) of the time for prandial bolus and basal insulin adjustments, respectively. Conclusions/interpretation The direction of insulin adjustments was comparable between physicians and the McGill algorithm. The large intra-physician variability further emphasises the subjective nature of insulin management. Graphical Abstract

  • Open Access

    Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial

    by Melissa‐Rosina Pasqua, Michael A. Tsoukas, Ahmad Haidar

    Background: There is little data on how semaglutide affects basal versus bolus insulin and dosing parameters in adults with type 1 diabetes on insulin pump therapy. Methods: This is a post‐hoc analysis of a double‐blinded, randomised, crossover trial assessing semaglutide (up to 1 mg) versus placebo during automated insulin delivery (AID). This analysis focuses on the first 11 of 15 weeks where participants used their routine pump therapy with continuous glucose monitoring (CGM), where remote follow‐ups were performed on days 7, 21, 32, 56, 63, and 77 (± 4 days). Changes in insulin requirements, carbohydrate input, and pump parameters over time compared to baseline were assessed, as well as the frequency of parameter adjustments. Results: Twenty‐six participants were included; 100% were using CGM and 81% using AID at baseline. Daily total and bolus insulin, along with carbohydrate input, were significantly reduced by day 7 and remained so, while basal was significantly reduced by day 32. By day 77, there was a median increase in carbohydrate ratios by 4.1% [−1.8, 7.7] and in correction factors by 11.2% [0.0, 20.8], and a reduction in pre‐programmed basal rates by 7.9% [−12.7, −4.2]. The median time spent in hypoglycemia was rarely >4% during these follow‐ups. Conclusions: Insulin needs decrease rapidly upon initiation of semaglutide use in type 1 diabetes on pump therapy, predominantly due to bolus changes from less carbohydrate consumption. While diabetes technology helps to reduce hypoglycemia, adjustments to pump dosing are still required.


  • A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System

    by Madison Odabassian, Michael A. Tsoukas, Elisa Cohen, Melissa-Rosina Pasqua, Joanna Rutkowski, Ahmad Haidar

    Background: Type 1 diabetes is treated with exogenous insulin using multiple daily injections or insulin pumps. However, both strategies require carbohydrate counting for prandial insulin dosing, which is both burdensome and error prone. Methods: We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system. The interventions included five arms during which participants underwent 14 hours of outpatient, free-living, supervised experiments of (1) faster aspart with carbohydrate counting (control), faster aspart and pramlintide without carbohydrate counting at (2) 8 µg/U and (3) 10 µg/U ratios, and aspart and pramlintide without carbohydrate counting at (4) 8 µg/U and (5) 10 µg/U ratios. Results: The median time in target range (3.9–10.0 mmol/L) with the control arm was 78.6 [65.3-92.9], compared with 76.2 [64.6-86.9] and 78.8 [68.8-86.0] with the fully closed-loop faster aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively, and compared with 65.9 [59.9-83.6] and 77.4 [72.1-82.7] with the fully closed-loop aspart and pramlintide systems at 8 and 10 µg/U ratios, respectively. Times spent below 3.9 and 3.0 mmol/L were numerically higher with the fully closed-loop aspart and pramlintide systems than the control arm. None of the differences were statistically significant. Conclusions: This study suggests that automated insulin and pramlintide systems have the potential to alleviate carbohydrate counting without degrading time in range. A longer and larger study is underway.


  • Open Access

    A Bayesian decision support system for automated insulin doses in adults with type 1 diabetes on multiple daily injections: a randomized controlled trial

    by Alessandra Kobayati, Anas El Fathi, Natasha Garfield, Laurent Legault, Adnan Jafar, Jean-François Yale, Michael A. Tsoukas, Ahmad Haidar

    Achieving optimal glycemic control remains challenging for many individuals with type 1 diabetes using multiple daily injections. We report results from a 12-week, open-label, randomized controlled trial evaluating a decision support system (DSS) consisting of a mobile application and a titration algorithm that provides weekly basal and prandial insulin recommendations. Eighty-four adults with type 1 diabetes and suboptimal glycemic control (HbA1c ≥ 7.5%) are randomized 1:1 to receive the DSS or a non-adaptive bolus calculator (control), alongside Freestyle Libre glucose sensors. The primary endpoint is change in HbA1c from baseline; secondary endpoints include additional glycemic and insulin-related metrics. The DSS reduces mean HbA1c from 8.6% (SD 1.1) to 8.1% (0.8) (p = 0.0002), while the control reduces HbA1c from 8.6% (1.0) to 8.5% (1.0) (p = 0.22); yielding a treatment effect of –0.40% (95% CI: –0.75 to –0.051; p = 0.025). There are no reported severe hypoglycemia or diabetic ketoacidosis events. Our DSS improves HbA1c in this population without compromising safety. ClinicalTrials.gov: NCT04123054 .


  • A Dual Stable Isotope Study of the Effect of Altitude and Simulated Flight on Glucose Metabolism in Type 1 Diabetes: A Randomized Crossover Study

    by Ka Siu Fan, Fariba Shojaee-Moradie, Fereshteh Jeivad, Antonios Manoli, Ahmad Haidar, Monique Borg Inguanez, Fiona Sammut, Gerd Koehler, Victoria Edwards, Vivienne Lee, et al.

    The impact of atmospheric pressure changes on glucose metabolism encountered in aviation on people with type 1 diabetes is controversial. A dual-isotope study was performed in a hypobaric chamber to simulate pressure changes experienced on commercial flights. The fasting and postprandial glucose kinetics of individuals with type 1 diabetes were evaluated across simulated in-flight cabin pressures (550 mmHg; experimental arm) and ground level (750 mmHg; control arm). The impact of ambient pressure on glucose disposal (Rd), endogenous glucose production (EGP), meal glucose appearance (Ra), and insulin concentrations were evaluated. Six male participants, aged 20–61 years, with a median BMI of 26.6 kg/m2, were studied. Baseline glucose Rd, EGP, and meal Ra values were not affected by ambient pressure changes. Postprandial glucose Rd was higher in hypobaric conditions than ground, the percent change in postprandial glucose concentration was lower, but postprandial EGP and meal Ra were not affected. Insulin concentration between 120 and 180 min was higher in the hypobaric simulation. The observed increase in glucose Rd for individuals with type 1 diabetes who were using insulin pumps may be related to the hypoxia and pressure changes experienced during flight. Because glucose profiles were unaffected, there is no evidence that insulin pump therapy is a risk factor in flight. Article Highlights: The effects of acute atmospheric pressure changes on glucose metabolism in type 1 diabetes remain controversial and may have safety implications for pilots and travelers alike. What are the differences in glucose kinetics and hormones between ground and simulated flight environments? Glucose disposal and insulin concentration are increased in response to a meal during flight, without associated changes in endogenous glucose production or meal glucose appearance rates. Pressure-related changes in insulin pump performance and hypoxia may explain these findings. Because glucose concentrations were unaffected, there is no evidence that insulin pump therapy is a risk factor in flight.


  • Top Cited Papers
    Open Access

    Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial

    by Melissa-Rosina Pasqua, Michael A. Tsoukas, Alessandra Kobayati, Wedyan Aboznadah, Adnan Jafar, Ahmad Haidar

    Efforts to improve glycemic control in type 1 diabetes are ongoing. We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes. At each intervention, participants were titrated up to 1 mg or the maximum tolerated dose of semaglutide or placebo over 11 weeks, followed by the use of an automated insulin delivery system for 4 weeks. The primary outcome was the percentage of time spent in the target glucose range of 3.9–10.0 mmol l−1 during the last 4 weeks of each intervention. Twenty-eight participants were randomized and 24 completed the trial. The primary endpoint was met. Compared to placebo, semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006), without increasing the time spent below 3.9 mmol l−1 (P = 0.19) or below 3.0 mmol l−1 (P = 0.65). While no diabetic ketoacidosis or severe hypoglycemia occurred during any of the interventions, there were two episodes of recurrent euglycemic ketosis without acidosis during semaglutide use. We conclude that semaglutide improves glycemic control with automated insulin delivery compared to placebo. ClinicalTrials.gov registration: NCT05205928